Recognition and Treatment of BCG Failure in Bladder Cancer
Patients with high-grade Ta, T1, or carcinoma in situ non–muscle-invasive bladder cancer (NMIBC) are at high risk for recurrence and, more importantly, progression. Thus, both the American Urological Association and European Association of Urology recommend initial intravesical treatment with bacill...
Saved in:
Main Authors: | Andrew J. Lightfoot, Henry M. Rosevear, Michael A. O'Donnell |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | The Scientific World Journal |
Online Access: | http://dx.doi.org/10.1100/tsw.2011.30 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rubin H. Flocks and Colloidal Gold Treatments for Prostate Cancer
by: Henry M. Rosevear, et al.
Published: (2011-01-01) -
Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer
by: Arjun Pon Avudaiappan, et al.
Published: (2024-11-01) -
Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer
by: Yi Luo, et al.
Published: (2011-01-01) -
Use of quasi-normal form to examine stability of tumor-free equilibrium in a mathematical model of bcg treatment of bladder cancer
by: Svetlana Bunimovich-Mendrazitsky, et al.
Published: (2011-03-01) -
Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections
by: J Alfred Witjes, et al.
Published: (2023-01-01)